Free Shipping on All Orders $75 Or More!

Your Trusted Brand for Over 35 Years

Life Extension Magazine

<< Back to October 2014

Assembly Line Medicine

October 2014

By William Faloon


  1. Lefranc F, Yeaton P, Brotchi J, Kiss R. Cimetidine, an unexpected anti-tumor agent, and its potential for the treatment of glioblastoma. Int J Oncol. 2006 May;28(5):1021-30.
  2. Natori T, Sata M, Nagai R, Makuuchi M. Cimetidine inhibits angiogenesis and suppresses tumor growth. Biomed Pharmacother. 2005 Jan-Feb;59(1-2):56-60.
  3. Tomita K, Izumi K, Okabe S. Roxatidine- and cimetidine-induced angiogenesis inhibition suppresses growth of colon cancer implants in syngeneic mice. J Pharmacol Sci. 2003 Nov;93(3):321-30.
  4. Matsumoto S, Imaeda Y, Umemoto S, Kobayashi K, Suzuki H, Okamoto T. Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells. Br J Cancer. 2002 Jan 21;86(2):161-7.
  5. Adams WJ, Lawson JA, Morris DL. Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth. Gut. 1994 Nov;35(11):1632-6.
  6. Adams WJ, Lawson JA, Nicholson SE, Cook TA, Morris DL. The growth of carcinogen-induced colon cancer in rats is inhibited by cimetidine. Eur J Surg Oncol. 1993 Aug;19 (4):332-5.
  7. Adams WJ, Morris DL, Ross WB, Lubowski DZ, King DW, Peters L. Cimetidine preserves nonspecific immune function after colonic resection for cancer. Aust N Z J Surg. 1994 Dec;64(12):847-52.
  8. Adams WJ, Morris DL. Short-course cimetidine and survival with colorectal cancer. Lancet. 1994 Dec 24-31;344(8939-8940):1768-9.
  9. Available at: Accessed June 24, 2014.
  10. Available at: Accessed July 12, 2014.
  11. Available at: Accessed July 12, 2014.
  12. Available at: Accessed July 12, 2014.
  13. Brivio F, Lissoni P, Rovelli F, et al. Effects of IL-2 preoperative immunotherapy on surgery-induced changes in angiogenic regulation and its prevention of VEGF increase and IL-12 decline. Hepatogastroenterology. 2002 Mar-Apr;49(44):385-7.
  14. Shankaran V, Ikeda H, Bruce AT, et al. IFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001 Apr 26;410(6832):1107-11.
  15. Fadul CE, Fisher JL, Hampton TH, et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother. 2011 May;34(4):382-9.
  16. Seeger RC. Immunology and immunotherapy of neuroblastoma. Semin Cancer Biol. 2011 Oct;21(4):229-37.
  17. Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011 Dec 1;118(23):6050-6.
  18. Ardon H, Van Gool S, Lopes IS, et al. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J Neurooncol. 2010 Sep;99(2):261-72.
  19. Smith C, Tsang J, Beagley L, et al. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res. 2012 Mar 1;72(5):1116-25.
  20. Miles SA, Sandler AD. CpG oligonucleotides for immunotherapeutic treatment of neuroblastoma. Adv Drug Deliv Rev. 2009 Mar 28;61(3):275-82.
  21. Available at: Accessed June 25, 2014.
  22. Available at: Accessed June 25, 2014.
  23. Hoogstraat M, de Pagter MS, Cirkel GA, van Roosmalen M J, Harkins TT, Duran, K, et al. Genomic and transcriptomic plasticity in treatment-naïve ovarian cancer. Genome Res. 2014 Feb;24(2):200-11.
  24. Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res. 2009;15(10):3251-55.
  25. Available at: . Accessed July 14, 2014.
  26. Huang Y, Shah S, Qiao L. Tumor resistance to CD8+ T cell-based therapeutic vaccination. Arch Immunol Ther Exp (Warsz). 2007 Jul-Aug;55(4):205-17.
  27. Huang Y, Obholzer N, Fayad R, Qiao L. Turning on/off tumor-specific CTL response during progressive tumor growth. J Immunol. 2005 Sep 1;175(5):3110-6.
  28. Speiser DE, Ohashi PS. Activation of cytotoxic T cells by solid tumours? Cell Mol Life Sci. 1998 Mar;54(3):263-71.
  29. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol. 2002 Jun;71(6):907-20.
  30. Sun S, Fei X, Mao Y, et al. PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer Immunol Immunother. 2014 Apr;63(4):395-406.
  31. Huang JJ, Jiang WQ, Lin TY, et al. Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Ann Oncol. 2011 Jan;22(1):149-55.
  32. Xu L, Xu W, Qiu S, Xiong S. Enrichment of CCR6+Foxp3+ regulatory T cells in the tumor mass correlates with impaired CD8+ T cell function and poor prognosis of breast cancer. Clin Immunol. 2010 Jun;135(3):466-75.
  33. Masmoudi A, Toumi N, Khanfir A, et al. Epstein-Barr virus-targeted immunotherapy for nasopharyngeal carcinoma. Cancer Treat Rev. 2007 Oct;33(6):499-505.
  34. Angelini C, Bovo G, Muselli P, et al. Preoperative interleukin-2 immunotherapy in pancreatic cancer: preliminary results. Hepatogastroenterology. 2006 Jan-Feb;53(67):141-4.
  35. Ratto GB, Costa R, Maineri P, et al. Neo-adjuvant chemo/immunotherapy in the treatment of stage III (N2) non-small cell lung cancer: a phase I/II pilot study. Int J Immunopathol Pharmacol. 2011 Oct-Dec;24(4):1005-16.
  36. Ludgate CM. Optimizing cancer treatments to induce an acute immune response: radiation Abscopal effects, PAMPs, and DAMPs. Clin Cancer Res. 2012 Sep 1;18(17):4522-5.
  37. Sarkar S, Döring A, Zemp FJ, et al. Therapeutic activation of macrophages and microglia to suppress brain tumor-initiating cells. Nat Neurosci. 2014 Jan;17(1):46-55.
  38. Antony GK, Dudek AZ. Interleukin 2 in cancer therapy. Curr Med Chem. 2010;17(29):3297-302.
  39. Maroto JP, del Muro XG, Mellado B, et al. Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC). Clin Transl Oncol. 2013 Sep;15(9):698-704.
  40. Weide B, Eigentler TK, Pflugfelder A, et al. Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. Cancer Immunol Immunother. 2011 Apr;60(4):487-93.
  41. Slavin S, Ackerstein A, Or R, et al. Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study. Cancer Immunol Immunother. 2010 Oct;59(10):1511-9.
  42. Vuoristo MS, Vihinen P, Skyttä T, Tyynelä K, Kellokumpu-Lehtinen P. Carboplatin and vinorelbine combined with subcutaneous interleukin-2 in metastatic melanoma with poor prognosis. Anticancer Res. 2009 May;29(5):1755-9.
  43. Hallett WH, Ames E, Alvarez M, et al. Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses. Biol Blood Marrow Transplant. 2008 Oct;14(10):1088-99.
  44. Lissoni P, Brivio F, Fumagalli L, Di Fede G, Brera G. Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy. In Vivo. 2005 Nov-Dec;19(6):1077-80.
  45. Quan WD Jr, Quan FM, Perez M, Johnson E. Outpatient intravenous interleukin-2 with famotidine has activity in metastatic melanoma. Cancer Biother Radiopharm. 2012 Sep;27(7):442-5.
  46. Hanzly M, Aboumohamed A, Yarlagadda N, et al. High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience. Urology. 2014 May;83(5):1129-34.
  47. Schäfer H, Hübel K, Bohlen H, et al. Perioperative treatment with filgrastim stimulates granulocyte function and reduces infectious complications after esophagectomy. Ann Hematol. 2000 Mar;79(3):143-51.
  48. Wenisch C, Werkgartner T, Sailer H, et al. Effect of preoperative prophylaxis with filgrastim in cancer neck dissection. Eur J Clin Invest. 2000 May;30(5):460-6.
  49. Hill G, Barron R, Fust K, et al. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin’s lymphoma: cost-effectiveness analyses. J Med Econ. 2014 Jan;17(1):32-42.
  50. Tesařová P. OPERa Study. Klin Onkol (Czech). 2013 26(6):425-33.
  51. Naeim A, Henk HJ, Becker L, Chia V, Badre S, Li X, Deeter R. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer. 2013 Jan 8;13:11.
  52. Hadji P, Kostev K, Schröder-Bernhardi D, Ziller V. Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany. Int J Clin Pharmacol Ther. 2012 Apr;50(4):281-9.
  53. Hirsch BR, Lyman GH. Pharmacoeconomics of the myeloid growth factors: a critical and systematic review. Pharmacoeconomics. 2012 Jun 1;30(6):497-511.
  54. Aapro MS, Bohlius J, Cameron DA, et al. European Organisation for Research and Treatment of Cancer. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011 Jan;47(1):8-32.
  55. Bonanno G, Procoli A, Mariotti A, et al. Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies. J Transl Med. 2010 Nov 9;8:114.
  56. Sehouli J, Goertz A, Steinle T, et al. Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany. Dtsch Med Wochenschr. 2010 Mar;135(9):385-9.
  57. Lyman G, Lalla A, Barron R, Dubois RW. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin’s lymphoma receiving CHOP-21 in United States. Curr Med Res Opin. 2009 Feb;25(2):401-11.
  58. Ramsey SD, Liu Z, Boer R, et al. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health. 2009 Mar-Apr;12(2):217-25.
  59. Waller EK. The role of sargramostim (rhGM-CSF) as immunotherapy. Oncologist. 2007 12 Suppl 2:22-6.
  60. Rini BI, Fong L, Weinberg V, Kavanaugh B, Small EJ. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor. J Urol. 2006 Jun;175(6):2087-91.
  61. Kurbacher CM, Kurbacher JA, Cramer EM, et al. Continuous low-dose GM-CSF as salvage therapy in refractory recurrent breast or female genital tract carcinoma. Oncology (Williston Park). 2005 Apr;19(4 Suppl 2):23-6.
  62. Heaney ML, Toy EL, Vekeman F, et al. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia. Cancer. 2009 Oct 15;115(20):4839-48.
  63. Available at: Accessed June 28, 2014.
  64. Albright JW, Albright JF. Impaired natural killer cell function as a consequence of aging. Exp Gerontol. 1998 Jan-Mar;33(1-2):13-25.
  65. Ogata K, Yokose N, Tamura H, et al. Natural killer cells in the late decades of human life. Clin Immunol Immunopathol. 1997 Sep;84(3):269-75.
  66. Kmiec Z, Myśliwska J, Rachón D, Kotlarz G, Sworczak K, Myśliwski A. Natural killer activity and thyroid hormone levels in young and elderly persons. Gerontology. 2001 Sep-Oct;47(5):282-8.
  67. Vitale M, Zamai L, Neri LM, et al. The impairment of natural killer function in the healthy aged is due to a postbinding deficient mechanism. Cell Immunol. 1992 Nov;145(1):1-10.
  68. Di Lorenzo G, Balistreri CR, Candore G, et al. Granulocyte and natural killer activity in the elderly. Mech Ageing Dev. 1999 Apr 1;108(1):25-38.
  69. McNerlan SE, Rea IM, Alexander HD, Morris TC. Changes in natural killer cells, the CD57CD8 subset, and related cytokines in healthy aging. J Clin Immunol. 1998 Jan;18(1):31-8.
  70. Dussault I, Miller SC. Decline in natural killer cell-mediated immunosurveillance in aging mice-a consequence of reduced cell production and tumor binding capacity. Mech Ageing Dev. 1994 Aug;75(2):115-29.
  71. Camous X, Pera A, Solana R, Larbi A. NK cells in healthy aging and age-associated diseases. BioMed Research International. 2012;2012:195956.
  72. Lutz CT, Quinn LS. Sarcopenia, obesity, and natural killer cell immune senescence in aging: altered cytokine levels as a common mechanism. Aging (Albany NY). 2012; 4(8):535-46.
  73. Wu J, Lanier LL. Natural killer cells and cancer. Adv Cancer Res. 2003 90:127-56.
  74. Lodoen MB, Lanier LL. Natural killer cells as an initial defense against pathogens. Curr Opin Immunol. 2006 Aug;18(4):391-8.
  75. Grégoire C, Chasson L, Luci C, et al. The trafficking of natural killer cells. Immunol Rev. 2007 Dec;220:169-82.
  76. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008 May;9(5):503-10.
  77. Mccoy JL, Rucker R, Petros JA. Cell-mediated immunity to tumor-associated antigens is a better predictor of survival in early stage breast cancer than stage, grade or lymph node status. Breast Cancer Res Treat. 2000 Apr;60(3):227-34.
  78. Koda K, Saito N, Takiguchi N, Oda K, Nunomura M, Nakajima N. Preoperative natural killer cell activity: c`orrelation with distant metastases in curatively research colorectal carcinomas. Int Surg. 1997 Apr-Jun;82(2):190-3.
  79. Da Costa ML, Redmond P, Bouchier-Hayes DJ. The effect of laparotomy and laparoscopy on the establishment of spontaneous tumor metastases. Surgery. 1998 Sep;124(3):516-25.
  80. Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol. 2003 Oct;10(8):972-92.
  81. McCulloch PG, MacIntyre A. Effects of surgery on the generation of lymphokine-activated killer cells in patients with breast cancer. Br J Surg. 1993 Aug;80(8):1005-7.
  82. Rosenne E, Shakhar G, Melamed R, Schwartz Y, Erdreich-Epstein A, Ben-Eliyahu S. Inducing a mode of NK-resistance to suppression by stress and surgery: a potential approach based on low dose of poly I-C to reduce postoperative cancer metastasis. Brain Behav Immun. 2007 May;21(4):395-408.
  83. Fehniger TA, Bluman EM, Porter MM, et al. Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. J Clin Invest. 2000 Jul;106(1):117-24.
  84. Caligiuri MA, Zmuidzinas A, Manley TJ, Levine H, Smith KA, Ritz J. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med. 1990 May 1;171(5):1509-26.
  85. Orange JS, Roy-Ghanta S, Mace EM, et al. IL-2 induces a WAVE2-dependent pathway for actin reorganization that enables WASp-independent human NK cell function. J Clin Invest. 2011 Apr;121(4):1535-48.
  86. Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995 Jul 15;86(2):457-62.
  87. Buchsel PC, DeMeyer ES. Dendritic cells: emerging roles in tumor immunotherapy. Clin J Oncol Nurs. 2006 Oct;10(5):629-40.
  88. Spitler LE. Adjuvant therapy of melanoma. Oncology (Williston Park). 2002 Jan;16(1 Suppl 1):40-8.
  89. Available at: Accessed July 2, 2014.
  90. Available at: . Accessed July 2, 2014.
  91. Peppercorn J, Burstein H, Miller FG, Winer E, Joffe S. Self-reported practices and attitudes of US oncologists regarding off-protocol therapy. J Clin Oncol. 2008 Dec 20;26(36):5994-6000.
  92. Available at: . Accessed June 23, 2014.
  93. Available at: . Accessed July 9, 2014.
  94. Available at: . Accessed July 9, 2014.
  95. Available at: Accessed July 9, 2014.
  96. Available at: . Accessed June 24, 2014.
  97. Available at: . Accessed June 24, 2014.
  98. Chattopadhyay M, Kodela R, Kashfi K. P09 Therapeutic potential of NOSH-aspirin, a dual nitric oxide- and hydrogen sulfide-donating hybrid in colon cancer. Nitric Oxide. 2013 Sep 1;31 Suppl 2:S37-8.
  99. Fraser DM, Sullivan FM, Thompson AM, McCowan C. Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study. Br J Cancer. 2014 Jun 19.
  100. Yue W, Yang CS, DiPaola RS, Tan XL. Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. Cancer Prev Res (Phila). 2014 Apr;7(4):388-97.
  101. Ucbek A, Ozünal ZG, Uzun O, Gepdıremen A. Effect of metformin on the human T98G glioblastoma multiforme cell line. Exp Ther Med. 2014 May;7(5):1285-90.
  102. Zhang ZJ, Bi Y, Li S, et al. Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis. Am J Epidemiol. 2014 Jul 1;180(1):11-4.
  103. Wang Z, Lai ST, Xie L, et al. Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2014 Apr 18.
  104. Fasih A, Elbaz HA, Hüttemann M, Konski AA, Zielske SP. Radiosensitization of Pancreatic Cancer Cells by Metformin through the AMPK Pathway. Radiat Res. 2014 Jul;182(1)50-9.
  105. Queiroz EA, Puukila S, Eichler R, et al. Metformin Induces Apoptosis and Cell Cycle Arrest Mediated by Oxidative Stress, AMPK and FOXO3a in MCF-7 Breast Cancer Cells. PLoS One. 2014 May 23;9(5):e98207.
  106. Takahashi A, Kimura F, Yamanaka A, et al. Metformin impairs growth of endometrial cancer cells via cell cycle arrest and concomitant autophagy and apoptosis. Cancer Cell Int. 2014 Jun 16;14:53.
  107. Joshua AM, Zannella VE, Downes MR, et al. A pilot ‘window of opportunity’ neoadjuvant study of metformin in localised prostate cancer. Prostate Cancer Prostatic Dis. 2014 May 27.
  108. Preston MA, Riis AH, Ehrenstein V, et al. Metformin Use and Prostate Cancer Risk. Eur Urol. 2014 May 21. pii: S0302-2838(14)00408-4.
  109. Zhang T, Zhang L, Zhang T, et al. Metformin Sensitizes Prostate Cancer Cells to Radiation Through EGFR/p-DNA-PKCS In Vitro and In Vivo. Radiat Res . 2014 Jun;181(6):641-9.
  110. Miyoshi H, Kato K, Iwama H, et al. Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. Int J Oncol. 2014 Jul;45(1):322-32.
  111. Cho SW, Yi KH, Han SK, et al. Therapeutic potential of metformin in papillary thyroid cancer in vitro and in vivo. Mol Cell Endocrinol. 2014 Jun 3;393(1-2):24-29.
  112. Yen YC, Lin C, Lin SW, Lin YS, Weng SF. Effect of metformin on the incidence of head and neck cancer in diabetes. Head Neck. 2014 May 7.
  113. Sun XJ, Zhang P, Li HH, Jiang ZW, Jiang CC, Liu H. Cisplatin combined with metformin inhibits migration and invasion of human nasopharyngeal carcinoma cells by regulating E-cadherin and MMP-9. Asian Pac J Cancer Prev. 2014 15(9):4019-23.
  114. Cerezo M, Tomic T, Ballotti R, Rocchi S. Is it time to test biguanide metformin in the treatment of melanoma? Pigment Cell Melanoma Res. 2014 May 24.
  115. Nenu I, Popescu T, Aldea MD, et al. Metformin associated with photodynamic therapy - A novel oncological direction. J Photochem Photobiol B. 2014 May 21;138C:80-91.
  116. Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer. 2007 May 1;109(9):1705-14.
  117. Quintás-Cardama A, Kantarjian H, Ravandi F, et al. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer. 2009 Jun 1;115(11):2482-90.
  118. Rickles FR, Falanga A, Montesinos P, Sanz MA, Brenner B, Barbui T. Bleeding and thrombosis in acute leukemia: what does the future of therapy look like? Thromb Res. 2007;120 Suppl 2:S99-106.
  119. Avvisati G, Tirindelli MC, Annibali O. Thrombocytopenia and hemorrhagic risk in cancer patients. Crit Rev Oncol Hematol. 2003 Oct 15;48(Suppl):S13-6.
  120. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014 May 21;311(19):1998-2006.
  121. Available at: . Accessed July 12, 2014.
  122. Available at: Accessed July 12, 2014.
  123. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003 Jun 1;97(11):2869-79.
  124. Delozier T, Vernhes JC. Comparative study of adriamycin, epirubicin and mitoxantrone in cancer of the breast. Review of the literature. Bull Cancer. 1991 Nov;78(11):1013-25.
  125. Wiseman LR, Spencer CM. Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. Drugs Aging. 1997 Jun;10(6):473-85.
  126. Henderson IC, Allegra JC, Woodcock T, et al. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol. 1989 May;7(5):560-71.
  127. Available at: . Accessed July 3, 2014.
  128. Available at: . Accessed July 3, 2014.
  129. Available at: . Accessed July 3, 2014.
  130. Available at: Accessed July 3, 2014.
  131. Soderberg-Naucler C, Rahbar A, Stragliotto G. Survival in patients with glioblastoma receiving valganciclovir. NEJM. Sep 5 2013;369(10):985-6.
  132. Dziurzynski K, Chang SM, Heimberger AB, et al. Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol. 2012 Mar 14(3):246-55.
  133. Barami K. Oncomodulatory mechanisms of human cytomegalovirus in gliomas. J Clin Neurosci. 2010 July 17(7):819-23.
  134. Soroceanu L, Cobbs CS. Is HCMV a tumor promoter? Virus Res. 2011 May 157(2):193-203.
  135. Available at: Accessed June 26, 2014.
  136. Available at: . Accessed June 26, 2014.
  137. Available at: . Accessed June 30, 2014.
  138. Available at: =. Accessed June 30, 2014.
  139. Available at: ?vgnextoid=19b381d71adc5410VgnVCM10000076192ca2RCRD&vgnextfmt=default . Accessed June 30, 2014.